News

Currently under development by Viamet Pharma,VT-1161 is intended for the treatment of fungal infections in humans. Viamet president and CEO Robert Schotzinger said in preclinical studies, VT-1161 has

KAI-4169, an intravenous (IV) formulation used in the treatment of secondary hyperparathyroidism (SHPT) in patients with chronic kidney disease-mineral and bone disorder (CKD-MBD), is in Phase 2 clinical

As per the agreement held during 2009, Pennsaid Viscous Solution is being handled by Nuvo’s licensee – Covidien and it has assumed all responsibility for managing, executing and

The agreement allows ChemPartner to conduct pre-clinical research activities, including target protein preparation and assay system establishment, generation and optimization of lead antibodies, as well as pharmacokinetic and

Perampanel is a highly selective, non-competitive a-amino-3-hydroxy-5-methyl-4-isoxazolepropionic acid (AMPA)-type glutamate receptor antagonist that has demonstrated anti-epileptic effects in Phase II and III studies. The clinical development plan for

The company has posted net loss of C$15.35m, as compared to net loss of C$1.59m for the year ago period. The basic and fully-diluted net loss per share

The US Food and Drug Administration (FDA) approved Aquoral is indicated for the treatment of xerostomia. PediatRx founder Cameron Durrant said they expect that Aquoral will help further

Vibativ is an once-daily injectable lipoglycopeptide antibacterial agent with a dual mechanism of action against Gram-positive bacteria, including resistant pathogens such as methicillin-resistant Staphylococcus aureus (MRSA). Astellas Pharma

In two Phase 1a studies, AVL-292 demonstrated a favorable safety, tolerability and pharmacokinetic profile in healthy volunteers. The trial is investigating the pharmacokinetics, safety and tolerability profile of